Mr. Hany Salama
Vice President, Worldwide Operations, NEOSTRATA COMPANY, INC.
Member of the Healthcare Council
Council Member Biography
Hany Salama, ME, MBA, CPM, CPSM, is the Vice President, Worldwide Operations at The NeoStrata Company. He has global responsibilities for commercial planning, supply chain, strategy, and distribution/manufacturing operations for all global marketed products. Mr. Salama has over 15 years of pharma/biotech industry experience with expertise in pharma/biotech portfolio management, lean six sigma, project management, supply chain management, product launches, and global outsourcing strategies for API's and finished product dosage forms. He is an Adjunct Professor at Rutgers University Graduate Business School and teaches Pharma Supply Chain, Management Strategy, and Operations Management and holds an Advisory Board seat at the Center for the Supply Chain. Mr. Salama conducts independent pharma/biotech industry research on the current outlook of the industry; mergers, acquisitions, innovative technologies, regulatory environment changes, and general trends of the pharma/biotech industry. (This is me - Update Profile)
Employment History
- 2008 - Unspecified
- Vice President, Worldwide Operations, NEOSTRATA COMPANY, INC.
- 2006 - 2008
- Director, Global Manufacturing and Pharmaceutical , BARRIER THERAPEUTICS, INC.
- 2002 - 2006
- Associate Director, Global Program Management, HOFFMANN-LA ROCHE INC.
- 2001 - 2002
- Project Engineer, MERCK SHARP & DOHME CORP.
- 1996 - 2001
- Operations Leader, BASF CORPORATION
GLG NewsSM Analyses by Hany Salama
GLG News is now G+ Insights
-
G+ is a community for professionals, academics and entrepreneurs to connect through online discussions and in-person meetings. You will continue to see G+ Insights (formerly GLG News) here as well as on the G+ website, where you can share and discuss the G+ Insights you read.
-
May 6, 2010
The concept of utilizing Contract Research Organizations (CROs) is not foreign to many large and small pharma and biotech organizations. However, in today's competitive markets, pharma and biotech organizations are looking beyond the costs savings and focusing on how they will be leveraging CROs to advance drug discovery and development. Organizations are now viewing CROs as a strategic asset and a key contributor to the drug development process.
-
Sterile Injectables Contract Manufacturing Market Outlook
February 28, 2008
Jubilant News for Hollister-Stier | www.contractpharma.com
As demand of the sterile injectables products grows, more and more contract manufacturers are evaluating this landscape as a potential opportunity for growth. The major concerns in this market outlook are how complex is the technology, how much capacity is needed and will this technology be the future for the pharmaceutical and biotech companies and are contract manufacturers ready/capable of the challenges.
-
Sustainable Cost Cutting Efforts Through Strategic Partnerships
January 25, 2008
Pfizer, Novartis, Amgen: cutting costs could boost short-term profits | www.pharmaceutical-business-review.com
In today's ever changing pharmaceutical/biotech landscape, manufacturers need to take an aggressive approach to reduce cost while developing their robust pipelines. To do this successfully, manufacturers need to focus on their core competencies as strategically determined by the senior management of the organization. Companies now need to focus on: 1. Outsourcing of none strategic activities such as manufacturing/packaging, some development activities and clinical operations 2. Look at strategic licensing partnerships to drive more enhanced pipelines 3. Continue to look at the global landscape to leverage effective operational opportunities
GLG Study Groups with Hany Salama(?)
| Study Group Name | No. Members |
|---|---|
| Generic Drug Economic Experts | 890 |
| Medical Device Experts | 513 |
| Specialty Chemical Experts | 390 |
| RFID Semiconductor Experts | 301 |
| Supply Chain Software Experts | 262 |
GLG Live Meetings with Hany Salama(?)
Hany Salama has not participated in any GLG Live Meetings.
Gerson Lehrman Group, Inc. connects communities with knowledge through two distinct, yet complementary offerings: GLG Research and G+.